AXIM Biotechnologies appoints Kurt Phinney as COO; grants option for 2M shares

AXIM BIOTECHNOLOGIES, INC.

Kurt Phinney appointed COO effective May 23, 2023; minimum six-month term.
Compensation: option to buy up to 2,000,000 shares (S-8), vesting 1/6 every 30 days.
Phinney's prior roles include VP Ops at Lumos Diagnostics and Versea Health.
Consulting agreement with Accalle, LLC (Phinney's entity); no cash salary.
Agreement may be terminated after initial term with 30 days' notice.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kurt Phinney

Chief Operating Officer

AXIM · AXIM BIOTECHNOLOGIES, INC.

Effective: 2023-05-23
Filed: May 25, 2023, 7:59 PM ET

On May 23, 2023, our Chief Executive Officer appointed Kurt Phinney as the Company’s Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kurt Phinney was appointed as Chief Operating Officer at AXIM BIOTECHNOLOGIES, INC..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On May 23, 2023, our Chief Executive Officer appointed Kurt Phinney as the Company’s Chief Operating Officer.

View on SEC.gov

AXIM BIOTECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001096906-23-001188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.